Evaluation of efficacy of Dimethyl Fumarate in stroke
Phase 2
Recruiting
- Conditions
- Ischemic Stroke.
- Registration Number
- IRCT20180224038841N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Patients at the age of 18-85 years old
Patients with acute neurological symptoms who have been diagnosed as ischemic stroke by a neurologist
Exclusion Criteria
Patients with prior sensitivity to dimethyl fumarate
Patients with serious infections
Pregnancy and lactation
Immunologic deficiencies in the past 6 months (i.e. cancer,lymphoma, HIV and viral hepatitis)
Patients receiving rtPA
Patients who undergo endovascular treatment
Liver function test more than 2 times of normal range
Initial WBC count under 3500
lymphopenia under 500
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Infarct Size in Magnetic Resonance Imaging(MRI). Timepoint: An MRI at the beginning of the trial and a second one after 15 to 45 days from starting Dimethyl fumarate or Placebo. Method of measurement: using automatic softwares.;National Institute of Health Stroke Scale (NIHSS). Timepoint: at the beginning of the trial and 30 days after starting Dimethyl fumarate. Method of measurement: NIHSS checklist.
- Secondary Outcome Measures
Name Time Method